Please assess the completion status of the following clinical trial:

Trial Title: Dexamethasone Dyspnea Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Diagnosis of cancer~2. Dyspnea with an average intensity level \>3/10 on the numeric rating scale over the past week~3. Clinical or radiologic history of lung/pleural involvement (primary or metastatic), lymphangitic carcinomatosis or airway involvement secondary to tumor infiltration~4. Outpatients at MD Anderson Cancer Center seen by the Supportive Care, Rehabilitation Service, Thoracic Oncology or Pulmonary Medicine~5. Able to communicate in English~6. Karnofsky performance status \>=40%~7. Age 18 or older~8. Permission from the attending medical oncologist if the patient is currently on an interventional cancer therapy trial.~Exclusion Criteria:~1. Delirium (i.e. Memorial delirium rating scale \>13)~2. Oxygen saturation \<90% despite supplemental oxygen \>6L/min~3. Previous allergic reactions to dexamethasone~4. Uncontrolled hyperglycemia as defined by any blood glucose of \>300 mg/dl in the past two weeks~5. Severe anemia (Hb \<7g/L) not corrected prior to study enrollment (bloodwork is not required if patient did not have recent chemotherapy within last 2 weeks)~6. Post-surgical open wound that has not been healed at the time of enrollment~7. Any infection requiring parenteral antibiotics within the past 2 weeks~8. Major surgery within the past 2 weeks~9. Megestrol use at the time of study enrollment~10. Neutropenia (absolute neutrophil count \< 1.0) (bloodwork is not required if patient did not have recent chemotherapy within last 2 weeks)~11. Currently on or expected to start cytotoxic chemotherapy with in 1 week of study enrollment~12. Chronic obstructive pulmonary disease (COPD) exacerbation at the time of study enrollment~13. Heart failure exacerbation at the time of study enrollment~14. Chronic systemic corticosteroid use (\>14 days) at the time of study enrollment~15. Unwilling to provide informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dexamethasone (Type: EXPERIMENTAL): Dexamethasone 8 mg (2 capsules of 4 mg) given orally twice a day for 4 days, then 4 mg given orally twice a day for 3 days. In the open label phase, patients assigned to either arm asked to take Dexamethasone 4 mg orally twice a day for 7 days. Patient to blow into spirometry machine 1 time a day to test lung function. Questionnaires completed at baseline and at day 7 and 14. It should take about 15 minutes to complete these questionnaires. Questionnaires completed at baseline and at day 7 and 14. It should take about 15 minutes to complete these questionnaires.~Participants randomized to either dexamethasone or placebo for 7 days in a blinded fashion; this will be followed by an open label phase in which patients in both arms would take dexamethasone for 7 days.
- Placebo (Type: PLACEBO_COMPARATOR): Two placebo capsules taken twice a day for 4 days, followed by one capsule twice a day for 3 days. Patient to blow into spirometry machine 1 time a day to test lung function. Questionnaires completed at baseline and at day 7 and 14. It should take about 15 minutes to complete these questionnaires. Questionnaires completed at baseline and at day 7 and 14. It should take about 15 minutes to complete these questionnaires.~Participants randomized to either dexamethasone or placebo for 7 days in a blinded fashion; this will be followed by an open label phase in which patients in both arms would take dexamethasone for 7 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).